COVID-19 – Asian Pacific Journal of Allergy and Immunology

January 2, 2023

COVID-19 Vaccine Allergy Safety Track (VAS-Track) pathway: real-world outcomes on vaccination rates and antibody protection

Misdiagnosed vaccine-related “allergies” lead to unnecessary vaccine deferrals and incomplete vaccinations, leaving patients unprotected against COVID-19. To overcome limitations and queues for Allergist assessment, the “VAS-Track” pathway was developed to evaluate patients via a multi-disciplinary triage model including nurses, non-specialists, and Allergists.

Allergy, antibody, COVID-19, safety, vaccine

January 4, 2022

A sero-epidemiological study after two waves of the COVID-19 epidemic

The COVID-19 situation in Maldives have evolved since the epidemic began in March 2020 with unprecedented increase in cases since mid-July 2019 with over 8000 cases at the end of August 2020.

age, antibody levels, COVID-19, Maldives, seroprevalence, Symptoms

October 4, 2021

Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets

A novel severe acute respiratory syndrome COVID-19 caused by coronavirus SARS-CoV-2 has been confirmed to infect more than 100 million people globally, with mortality reaching nearly 3 million as of March 2021.

COVID-19, hyperimmune activation, immunopathology, Innate immunity, SARS-CoV-2

April 26, 2021

Asthma does not increase COVID-19 mortality and poor outcomes: A systematic review and meta-analysis

The Center for Disease Control and Prevention (CDC) has mentioned Coronavirus Disease 2019 (COVID-19) patients with moderate or severe asthma as a high risk group for severe illness. While WHO mentioned only chronic respiratory diseases, not specifically asthma as a risk factor for severe illness. There has been asthma prevalence discrepancy in studies of COVID-19 across the world.

Asthma, Corticosteroid, COVID-19, Mortality, Poor Outcome

January 30, 2021

Anxiety and depression in allergic rhinitis patients during COVID-19 pandemic in Wuhan, China

During COVID-19 pandemic, many allergic rhinitis (AR) patients stopped their treatment including pharmacotherapy and allergen immunotherapy.

Allergic rhinitis, anxiety, COVID-19, depression, VAS

December 29, 2020

Social restriction versus herd immunity policies in the early phase of the SARS-CoV-2 pandemic: A mathematical modelling study

Two main strategies to cope with the coronavirus disease 2019 (COVID-19) pandemic—lockdown (social restriction) and non-lockdown (herd immunity plan)—have been implemented in several countries.

control strategy, COVID-19, lockdown, mortality rate, SARS-CoV-2